Differential Effect of Eculizumab and Efgartigimod on Subscores of the MG-ADL and QMG in Generalized Myasthenia Gravis Patients (P1-11.017)
Objective of our study is to describe the differential response of innovative treatments on subscores of the Myasthenia Graves activities of daily living (MG-ADL), and quantitative MG scale (QMG) in a real-life setting.
Authors
- Chiara Pane (ORCID: https://orcid.org/0000-0002-3459-2644)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- Giorgia Puorro
- Angela Marsili (ORCID: https://orcid.org/0000-0002-4508-9825)
- Nunzia Cuomo
- Alessio Sarnataro (ORCID: https://orcid.org/0009-0008-5042-4799)
- Angelo Rendina
Institutions
- Federico II University Hospital (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212016
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00